BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

361 related articles for article (PubMed ID: 33226447)

  • 21. Wild type Kirsten rat sarcoma is a novel microRNA-622-regulated therapeutic target for hepatocellular carcinoma and contributes to sorafenib resistance.
    Dietrich P; Koch A; Fritz V; Hartmann A; Bosserhoff AK; Hellerbrand C
    Gut; 2018 Jul; 67(7):1328-1341. PubMed ID: 29275358
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Complex formation of sphingomyelin synthase 1 with glucosylceramide synthase increases sphingomyelin and decreases glucosylceramide levels.
    Hayashi Y; Nemoto-Sasaki Y; Matsumoto N; Hama K; Tanikawa T; Oka S; Saeki T; Kumasaka T; Koizumi T; Arai S; Wada I; Yokoyama K; Sugiura T; Yamashita A
    J Biol Chem; 2018 Nov; 293(45):17505-17522. PubMed ID: 30242129
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Treatment with a New Barbituric Acid Derivative Exerts Antiproliferative and Antimigratory Effects against Sorafenib Resistance in Hepatocellular Carcinoma.
    Liao YJ; Hsu SM; Chien CY; Wang YH; Hsu MH; Suk FM
    Molecules; 2020 Jun; 25(12):. PubMed ID: 32575795
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Artesunate Sensitizes human hepatocellular carcinoma to sorafenib via exacerbating AFAP1L2-SRC-FUNDC1 axis-dependent mitophagy.
    Ma Z; Chen W; Liu Y; Yu L; Mao X; Guo X; Jiang F; Guo Q; Lin N; Zhang Y
    Autophagy; 2024 Mar; 20(3):541-556. PubMed ID: 37733919
    [TBL] [Abstract][Full Text] [Related]  

  • 25. LY3214996 relieves acquired resistance to sorafenib in hepatocellular carcinoma cells.
    Ma Y; Xu R; Liu X; Zhang Y; Song L; Cai S; Zhou S; Xie Y; Li A; Cao W; Tang X
    Int J Med Sci; 2021; 18(6):1456-1464. PubMed ID: 33628103
    [No Abstract]   [Full Text] [Related]  

  • 26. LncRNA FOXD2-AS1 as a competitive endogenous RNA against miR-150-5p reverses resistance to sorafenib in hepatocellular carcinoma.
    Sui C; Dong Z; Yang C; Zhang M; Dai B; Geng L; Lu J; Yang J; Xu M
    J Cell Mol Med; 2019 Sep; 23(9):6024-6033. PubMed ID: 31210410
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Increased expression of SLC46A3 to oppose the progression of hepatocellular carcinoma and its effect on sorafenib therapy.
    Zhao Q; Zheng B; Meng S; Xu Y; Guo J; Chen LJ; Xiao J; Zhang W; Tan ZR; Tang J; Chen L; Chen Y
    Biomed Pharmacother; 2019 Jun; 114():108864. PubMed ID: 30981107
    [TBL] [Abstract][Full Text] [Related]  

  • 28. All members in the sphingomyelin synthase gene family have ceramide phosphoethanolamine synthase activity.
    Ding T; Kabir I; Li Y; Lou C; Yazdanyar A; Xu J; Dong J; Zhou H; Park T; Boutjdir M; Li Z; Jiang XC
    J Lipid Res; 2015 Mar; 56(3):537-545. PubMed ID: 25605874
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sphingomyelin synthase 2 activity and liver steatosis: an effect of ceramide-mediated peroxisome proliferator-activated receptor γ2 suppression.
    Li Y; Dong J; Ding T; Kuo MS; Cao G; Jiang XC; Li Z
    Arterioscler Thromb Vasc Biol; 2013 Jul; 33(7):1513-20. PubMed ID: 23640498
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Development of a quantitative biochemical and cellular sphingomyelin synthase assay using mass spectrometry.
    Chen Y; Yurek DA; Yu L; Wang H; Ehsani ME; Qian YW; Konrad RJ; Jiang XC; Kuo MS; Cao G; Wang J
    Anal Biochem; 2013 Jul; 438(1):61-6. PubMed ID: 23535273
    [TBL] [Abstract][Full Text] [Related]  

  • 31. ID1-induced p16/IL6 axis activation contributes to the resistant of hepatocellular carcinoma cells to sorafenib.
    Niu LL; Cheng CL; Li MY; Yang SL; Hu BG; Chong CCN; Chan SL; Ren J; Chen GG; Lai PBS
    Cell Death Dis; 2018 Aug; 9(9):852. PubMed ID: 30154433
    [TBL] [Abstract][Full Text] [Related]  

  • 32. PFKFB3/HIF-1α feedback loop modulates sorafenib resistance in hepatocellular carcinoma cells.
    Long Q; Zou X; Song Y; Duan Z; Liu L
    Biochem Biophys Res Commun; 2019 Jun; 513(3):642-650. PubMed ID: 30981500
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hypoxia-mediated sorafenib resistance can be overcome by EF24 through Von Hippel-Lindau tumor suppressor-dependent HIF-1α inhibition in hepatocellular carcinoma.
    Liang Y; Zheng T; Song R; Wang J; Yin D; Wang L; Liu H; Tian L; Fang X; Meng X; Jiang H; Liu J; Liu L
    Hepatology; 2013 May; 57(5):1847-57. PubMed ID: 23299930
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Long Noncoding RNA MALAT1 Contributes to Sorafenib Resistance by Targeting miR-140-5p/Aurora-A Signaling in Hepatocellular Carcinoma.
    Fan L; Huang X; Chen J; Zhang K; Gu YH; Sun J; Cui SY
    Mol Cancer Ther; 2020 May; 19(5):1197-1209. PubMed ID: 32220970
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Sphingomyelin synthase SMS2 displays dual activity as ceramide phosphoethanolamine synthase.
    Ternes P; Brouwers JF; van den Dikkenberg J; Holthuis JC
    J Lipid Res; 2009 Nov; 50(11):2270-7. PubMed ID: 19454763
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hedgehog signaling promotes sorafenib resistance in hepatocellular carcinoma patient-derived organoids.
    Wang S; Wang Y; Xun X; Zhang C; Xiang X; Cheng Q; Hu S; Li Z; Zhu J
    J Exp Clin Cancer Res; 2020 Jan; 39(1):22. PubMed ID: 31992334
    [TBL] [Abstract][Full Text] [Related]  

  • 37. DNMT3b/OCT4 expression confers sorafenib resistance and poor prognosis of hepatocellular carcinoma through IL-6/STAT3 regulation.
    Lai SC; Su YT; Chi CC; Kuo YC; Lee KF; Wu YC; Lan PC; Yang MH; Chang TS; Huang YH
    J Exp Clin Cancer Res; 2019 Nov; 38(1):474. PubMed ID: 31771617
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A novel multitarget kinase inhibitor BZG with potent anticancer activity in vitro and vivo enhances efficacy of sorafenib through PI3K pathways in hepatocellular carcinoma cells.
    Wang L; Zhan Y; Wu Z; Lin M; Jin X; Jiang L; Qiu Y
    Biomed Pharmacother; 2020 May; 125():110033. PubMed ID: 32187962
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Targeting glucosylceramide synthase upregulation reverts sorafenib resistance in experimental hepatocellular carcinoma.
    Stefanovic M; Tutusaus A; Martinez-Nieto GA; Bárcena C; de Gregorio E; Moutinho C; Barbero-Camps E; Villanueva A; Colell A; Marí M; García-Ruiz C; Fernandez-Checa JC; Morales A
    Oncotarget; 2016 Feb; 7(7):8253-67. PubMed ID: 26811497
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Modulation of SIRT3 expression through CDK4/6 enhances the anti-cancer effect of sorafenib in hepatocellular carcinoma cells.
    Jo H; Park Y; Kim T; Kim J; Lee JS; Kim SY; Chung JI; Ko HY; Pyun JC; Kim KS; Lee M; Yun M
    BMC Cancer; 2020 Apr; 20(1):332. PubMed ID: 32306906
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.